



TITLE:

Difference in fine specificity to polysaccharides of *Candida albicans* mannoprotein between mouse SIGNR1 and human DC-SIGN.

AUTHOR(S):

Takahara, Kazuhiko; Arita, Takuya; Tokieda, Sumika; Shibata, Nobuyuki; Okawa, Yoshio; Tateno, Hiroaki; Hirabayashi, Jun; Inaba, Kayo

CITATION:

Takahara, Kazuhiko ...[et al]. Difference in fine specificity to polysaccharides of *Candida albicans* mannoprotein between mouse SIGNR1 and human DC-SIGN.. *Infection and immunity* 2012, 80(5): 1699-1706

ISSUE DATE:

2012-05

URL:

<http://hdl.handle.net/2433/156138>

RIGHT:

© 2012, American Society for Microbiology.; この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

**Difference in fine specificity to polysaccharides of *C. albicans* mannoprotein
between mouse SIGNR1 and human DC-SIGN**

Kazuhiko Takahara^{1*}, Takuya Arita¹, Sumika Tokieda¹, Nobuyuki Shibata², Yoshio Okawa²,
Hiroaki Tateno³, Jun Hirabayashi³ and Kayo Inaba^{1*¶}

Running title: *Recognition of C. albicans polysaccharides by SIGNR1*

From ¹Department of Animal Development and Physiology, Graduate School of Biostudies, and
^{*}CREST, Kyoto University, Yoshida-Konoe, Sakyo, Kyoto, Kyoto 606-8501, Japan,
²Department of Infection and Host Defense, Tohoku Pharmaceutical University, Aoba,
Komatsushima 4-4-1, Sendai, Miyagi 981-8558, Japan, and ³Research Center for Medical
Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST), AIST
Tsukuba Central 2, 1-1-1 Umezono, Ibaraki 305-8568, Japan.

¶Address correspondence to: Dr. Kayo Inaba, Laboratory of Immunobiology, Department of
Animal Development and Physiology, Division of Systemic Life Science, Graduate School of
Biostudies, Kyoto University, Yoshida-Konoe, Sakyo, Kyoto 606-8501, Japan.
Phone: +81-75-753-4088, Fax: +81-75-753-4112, E-mail: kayo@lif.kyoto-u.ac.jp

20

21 **Abbreviations used in this paper:** antibody, Ab; carbohydrate recognition domain, CRD;
22 fluorescein isothiocyanate, FITC; human DC-SIGN, hDC-SIGN; monoclonal antibody, mAb;
23 phycoerythrin, PE; phosphorylated mannose, PM; RAW264.7 cells expressing human DC-SIGN,
24 RAW-hDC-SIGN; RAW264.7 cells expressing hDC-SIGN of which CRD is replaced with
25 SIGNR1 CRD, RAW-chimera; RAW264.7 cells expressing SIGNR1, RAW-SIGNR1; soluble
26 lectin, sLectin; soluble form SIGNR1, sSIGNR1; soluble form human DC-SIGN, shDC-SIGN;
27 toll-like receptors, TLRs.

28

28 Abstract

29 C-type lectin SIGNR1 directly recognizes *Candida albicans* and zymosan, and has
30 been considered to share properties of polysaccharide recognition with human (h)DC-SIGN.
31 However, the precise specificity of SIGNR1 and difference from that of hDC-SIGN remains to
32 be elucidated. We prepared soluble forms of SIGNR1 and hDC-SIGN and conducted
33 experiments to examine their respective specificities.

34 Soluble SIGNR1 (sSIGNR1) bound several types of live clinical isolate *C. albicans*
35 strains in an EDTA-sensitive manner. Inhibition analyses of sSIGNR1 binding by glycans from
36 various yeast strains demonstrated that SIGNR1 preferentially recognizes N-glycan α -mannose
37 side chains in *Candida* mannoproteins, as reported in hDC-SIGN. Unlike shDC-SIGN, however,
38 sSIGNR1 recognized not only *S. cerevisiae* but also *C. albicans* J-1012 glycan even after
39 α -mannosidase treatment that leaves only β 1,2-mannose capped α -mannose side chains. In
40 addition, the glyco-microarray analyses showed that sSIGNR1 binds mannans from *C. albicans*
41 and *S. cerevisiae*, but does not recognize Lewis^{a/b/x/y} antigen polysaccharides as in shDC-SIGN.
42 Consistent with these results, RAW264.7 cells expressing hDC-SIGN of which the carbohydrate
43 recognition domain (CRD) was replaced with that of SIGNR1 (RAW-chimera) produced
44 comparable amounts of IL-10 in response to glycans from *C. albicans* and *S. cerevisiae*, but
45 those expressing hDC-SIGN produced less IL-10 to *S. cerevisiae* than *C. albicans*. Furthermore,
46 RAW-hDC-SIGN cells remarkably reduced IL-10 production after α -mannosidase treatment

47 compared with RAW-chimera.

48 These results indicate that SIGNR1 recognizes *C. albicans*/yeast through a partly

49 distinct specificity from its homologue hDC-SIGN.

50

Introduction

Numerous microbes are covered with the polysaccharides. Recognition of the polysaccharides by pattern recognition receptors (PRRs), including lectins, is vital in order to recognize pathogens, since recognition of the outermost components is the first interactive step with immune cells during infection to evoke innate and adaptive immune responses.

Candida albicans is an opportunistic agent of infection in immune compromised patients. In the host innate immune system, several types of receptors for sensing ligands on the microbe have been defined, *e.g.*, C-type lectins and toll-like receptors (TLRs) (18). Ligands for these receptors are present in the outer structure of microbes. However, some ligands are sequestered by the outermost polysaccharides, which consist of mannoproteins, as reported in the case of β -glucan, a ligand for Dectin-1 (6). Mannoproteins are rich in polysaccharides composed of mostly α - and β -mannose and recognized by mannose/mannan type lectins.

C-type lectin human (h)DC-SIGN (CD209) has been shown to interact with a wide range of pathogens, including microbes, viruses and protozoa (11) *via* mannose and fucose moieties on the surface of the pathogens. Microbes such as *Mycobacterium tuberculosis* and *C. albicans* are endocytosed and processed for antigen presentation to induce the subsequent T cell-mediated immune responses. However, the recognition also induces immunosuppressive responses in cooperation with TLRs (8).

Mice have eight hDC-SIGN homologues (19, 20). One of these homologues, SIGNR1,

is structurally related to hDC-SIGN based on its long neck domain. SIGNR1 is expressed on particular subsets of macrophages (M ϕ)/dendritic cells (DC) in the marginal zones of the spleen, resident peritoneal cavity, medulla of lymph nodes, skin and lamina propria (4, 10, 17, 30). SIGNR1 on these cells plays a role as a sentinel in the recognition of pathogens through capsular polysaccharides. In fact, SIGNR1 on marginal zone M ϕ recognizes *Streptococcus pneumoniae* (10), leading to efficient activation of the complement system *in situ* (9).

Previously, we reported that SIGNR1 recognizes Gram-negative bacteria (*Salmonella typhimurium* and *Escherichia coli*) and *C. albicans* (27). The former are recognized through their non-reductive end of the lipopolysaccharide core sequence by SIGNR1 (17). This is also the case of hDC-SIGN in recognition of *E. coli* (13). Recently, hDC-SIGN has been reported to strongly recognize the α -mannose structure of N-glycan side chains of *C. albicans*, but weakly that of *S. cerevisiae* (2). However, the recognition motif on *C. albicans* by SIGNR1 is not clear at present.

Therefore, we aimed to elucidate the properties of SIGNR1 in the recognition of polysaccharide on *C. albicans*. To this end, we prepared soluble forms of SIGNR1 (sSIGNR1) and hDC-SIGN (shDC-SIGN) and used structurally distinguished glycans purified from various types of *C. albicans* and *S. cerevisiae* as well as respective microbes. The results indicate that sSIGNR1 binds equally well to glycans from *S. cerevisiae* as to *C. albicans*. Furthermore, sSIGNR1, but not shDC-SIGN, was shown to readily recognize *C. albicans* glycan treated with α -mannosidase. In addition, a glyco-microarray based on an evanescent-field fluorescence

88 detection method clearly revealed that sSIGNR1 binds α -mannose monosaccharide and mannans
89 from *C. albicans* and *S. cerevisiae*, but dose not recognize Lewis^{a/b/x/y} antigen polysaccharides as
90 in shDC-SIGN. Different properties in recognition of yeast glycans between SIGNR1 and
91 hDC-SIGN CRD were also observed in induction of IL-10 from RAW264.7 cells.

92

92 **Materials and methods**

93 **Cells and cultures.** Maintenance of human embryonic kidney (HEK) 293T cells and
94 macrophage-like RAW264.7 cells and preparation of RAW264.7 expressing SIGNR1
95 (RAW-SIGNR1) were as described previously (27). In order to prepare RAW-hDC-SIGN,
96 cDNA encoded hDC-SIGN (kindly provided by Dr. R.M. Steinman, Rockefeller University) was
97 cloned into pMX-IRES-puromycin (12). RAW264.7 cells were transfected by the plasmid with
98 Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's protocol.
99 RAW264.7 cells expressing hDC-SIGN (RAW-hDC-SIGN) were maintained in the presence of
100 4 µg/ml puromycin (InvivoGen, San Diego, CA). To prepare RAW264.7 cells expressing
101 chimeric lectin consisting of hDC-SIGN and SIGNR1 (RAW-chimera), cDNA fragments
102 encoding amino acids 1 - 253 (corresponding to cytosolic-neck domain of hDC-SIGN) and 193 -
103 325 (corresponding to CRD of SIGNR1) were amplified using KOD polymerase (Toyobo,
104 Tokyo, Japan) using primer pairs (5'-ggtggtacgggaattcatgagtgactccaaggaaccaagac-3',
105 5'-ggcacaggcgttcac-3') and (5'-tggaacgcctgtgccgactctgccctgggactggacattc-3',
106 5'-atttagctagcggccgcctagccttcagtgcattggggttc-3'), respectively. These were introduced into *Eco*
107 RI - *Not* I site of pMX-IRES-puromycin using the In-Fusion PCR Cloning System (Clontech,
108 Mountain View, CA). RAW264.7 cells were transfected by the plasmid as described above.
109
110 **Reagents and yeast strains.** Alexa647-coupled hamster anti-SIGNR1 mAb 22D1 and rabbit

111 anti-hDC-SIGN Ab (H-200) were purchased from eBioscience (San Diego, CA) and Santa Cruz
112 Biotechnology (Santa Cruz, CA), respectively. Anti-hDC-SIGN mAb (DCS-8C1; eBioscience)
113 was labeled with Alexa-555 (Invitrogen) in accordance with the manufacturer's protocol.
114 Glycogen of bovine liver type IX (G0885) and Jack bean (*Canavalia ensiformis*) α -mannosidase
115 (EC 3.2.1.24) were from Sigma-Aldrich (Irvine, CA). *C. albicans* (J-1012: serotype A,
116 NBRC1060 and NIH B-792: serotype B, NBRC10108), *C. lusitaniae* (NBRC1019) and *S.*
117 *cerevisiae* X2180-1A (WT) (BY21559) were obtained from the Biological Resource Center of
118 the National Institute of Technology and Evaluation (Tokyo, Japan). *C. albicans* (JCM1542) was
119 from the Japan Collection of Microorganisms, RIKEN (Saitama, Japan).

120
121 **Preparation of mannan from yeast strains.** Glycan was prepared from mannoprotein of the
122 blastospore (yeast) form using Fehling's solution, as previously described (24). Glycans used in
123 this study were purified from strains of *C. albicans* J-1012 (25), *C. albicans* NIH B-792 (22), *C.*
124 *stellatoidea* (24), *C. parapsilosis* (22), *C. lusitaniae* (23), *S. cerevisiae* (WT) (1), *S. cerevisiae*
125 (*mnn1/mnn4*) (1) and *S. cerevisiae* (*mnn2*) (21). The α -mannosidase treatment of *C. albicans*
126 J-1012 mannan was carried out in 50 mM sodium acetate buffer (pH 4.6) containing 20 units of
127 α -mannosidase at 37°C for 48 h.

128
129 **Preparation of sSIGNR1 and shDC-SIGN and binding analyses to microbes.** Soluble lectin

(sLectin) tetramers, such as sSIGNR1 and shDC-SIGN, were prepared as described (26). Briefly, cDNA fragments encoding their extracellular domains were cloned into pEXPR-IBA44 (IBA, Göttingen, Germany) to add N-terminal BM40 secretion signal and *Strep*-Tag II sequences, followed by the transfer into pEF6/V5-His (Invitrogen). HEK293T cells were then transfected with each plasmid using the calcium phosphate method (3) and cultured in serum-free medium 293 SFM II (Invitrogen) for the last 48 hr. sSIGNR1 and shDC-SIGN in the supernatant were purified using *Strep*-Tactin Sepharose (IBA) in accordance with the manufacturer's protocol (> 95% of purity by SDS-PAGE).

Purified sLectins (2.5 µg/ml) were incubated with PE-labeled *Strep*-Tactin (7.5 µg/ml) in 18 µl of Hanks' balanced salt solution (pH 8.3) (binding buffer) for 2 h at 4°C and for a further 10 min at 37°C. The tetramers thus formed were incubated with 5×10^6 live microbes for 4 h at 4°C in the presence of 1% BSA (total volume 25 µl). After washing with the binding buffer, the amount of bound PE-*Strep*-Tactin was measured by Gemini EM (Molecular Devices, Sunnyvale, CA). The direct binding of sSIGNR1 is shown as an arbitrary unit of fluorescence intensity. The % inhibition was calculated using the following formula: $[1 - (\text{fluorescence intensity of } C. \text{ albicans} \text{ by the staining with sLectin plus inhibitor} - \text{that without sLectin}) / (\text{that with sLectin without inhibitor} - \text{that without sLectin})] \times 100$.

Lectin ELISA. sSIGNR1 and shDC-SIGN were formed by incubating sLectins (62.5 ng) with

149 HRP-*Strep*-Tactin (12.5 ng) in 20 μ l of the solution as above. Microtiter plates were coated with
150 50 μ l of mannan/glycan (5 mg/ml) in 50 mM sodium bicarbonate buffer (pH 9.6) for 12 h at 4°C,
151 followed by the incubation with 2.5% BSA at room temperature for 2 h after washing with 25
152 mM Tris-HCl pH8.3 + 150 mM NaCl. The plates were then incubated with sSIGNR1 or
153 shDC-SIGN in the presence of 1% BSA for 2 h at 4°C. For inhibition experiments, sLectin
154 tetramer was pre-incubated with inhibitors for 1 h at 4°C before adding to plates. After washing,
155 binding of sLectin tetramer was measured as the absorbance of TMB (eBioscience) at 450 nm by
156 VERSAmax (Molecular Devices). The % inhibition was calculated as above.

157
158 **Inhibition of FITC-dextran binding to RAW-SIGNR1 with glycans.** RAW-SIGNR1 cells (2
159 $\times 10^5$ cells) were pre-incubated with various types of glycan and EDTA (25 mM) for 30 min at
160 4°C and then mixed with 80 μ g/ml of FITC-dextran (2,000 kDa; Sigma-Aldrich) for 4 h at 4°C.
161 Binding of FITC-dextran was analyzed by a flow cytometer. The % inhibition was calculated
162 using the following formula: $[1 - (\text{mean fluorescence intensity (MFI) of RWA-SIGNR1 cells}$
163 $\text{with FITC-dextran plus inhibitor} - \text{that without FITC-dextran}) / (\text{that with FITC-dextran without}$
164 $\text{inhibitor} - \text{that without FITC-dextran})] \times 100$.

165
166 **Glyco-microarray analyses of sLectins by evanescent-field fluorescence detection.** The
167 glyco-microarray analysis was performed as described (28). To form immune complex,

168 sSIGNR1 and shDC-SIGN (10 μ g/ml) were pre-incubated with Alexa647-anti-SIGNR1 (22D1)
169 and Alexa555-anti-hDC-SIGN (DCS-8C1; 1 μ g/ml) for 15 min at room temperature in 25 mM
170 Tris-HCl buffer (pH 7.4) containing 0.8% NaCl, 1% (v/v) Triton-X100, and 2 mM CaCl_2 with or
171 without 10 mM EDTA. This complex was directly added to the array immobilized with
172 multivalent glycan ligands (Supplementary Fig. S1), followed by incubation overnight at 20°C.
173 Binding was then detected using an evanescent-field fluorescence-assisted scanner. Data were
174 analyzed with the Array Pro analyzer ver. 4.5 (Media Cybernetics, Bethesda, MD).

175
176 **IL-10 production of RAW264.7 transfectants by stimulation in microplates coated with**
177 **glycan.** Non-treated plates were pre-coated with 600 μ g/ml glycan in PBS for 12 h. After
178 blocking with RPMI1640 containing 10% FCS for 30 min, RAW264.7 transfectants (5×10^4
179 cells) were cultured in the presence of 100 ng/ml ultra pure LPS (Invitrogen) for 24 h. IL-10 in
180 the supernatants was analyzed using the Cytometric Bead Array (CBA) for mouse inflammation
181 kit (BD Biosciences, Franklin Lakes, NJ).

182
183 **Statistical analysis.** Data are expressed as the means \pm SD of triplicate assays. Statistical
184 significance was determined by the two-tailed Student's *t*-test or multiple comparisons with
185 Tukey's multiple range test. All experiments were performed two or more times and
186 representative results are shown.

187

Results and Discussion

SIGNR1 recognizes various types of Candida strains. Each Candida strain has a unique set of oligomannose side chains, generating a great diversity of N-glycans (see Fig. 1A) compared with that of O-glycans. Moreover, N-glycans account for more than 95% of glycans in the surface mannoproteins.

Therefore, we first examined the direct binding of sSIGNR1 to several Candida strains (Fig. 1B). We used sSIGNR1 tetramerized with *Strep*-Tactin, because the affinity of sSIGNR1 monomer is weak (20). This method not only helps to increase the affinity of sSIGNR1 but also helps to avoid the formation of large complexes using Fc-fusion lectins polymerized with anti-Fc polyclonal Ab. Before using this sSIGNR1-tetramer for experiments, we confirmed that sSIGNR1-tetramer bound to mannan-agarose was eluted with EDTA (data not shown), although the yield was less than half the amounts applied. sSIGNR1 bound clinical isolate live *C. albicans* JCM1542 (serotype A) in an EDTA-sensitive manner, indicating that sSIGNR1 binding occurs *via* the carbohydrate recognition domain (CRD). The other clinical isolate strains, *C. albicans* J-1012 (serotype A) and NIH B-792 (serotype B), were also recognized by sSIGNR1, although sSIGNR1 binding was much less to nosocomial strain *C. lusitaniae*.

It is of note that sSIGNR1 binds to *S. cerevisiae* comparably to clinical isolate *C. albicans* (Fig. 1B), and its binding to *C. albicans* J-1012 microbes was equally inhibited by N-glycans from *S. cerevisiae* (WT and *mnn1/mnn4*) and *C. albicans* NIH B-792 as *C. albicans*

206 J-1012 (Fig. 1C).

207

208 **SIGNR1 possibly recognizes α -mannose in side chains of *C. albicans* N-glycan.** To delineate
209 the polysaccharide structure recognized by SIGNR1, inhibition experiments with lectin ELISA
210 were conducted using N-glycans from the various yeast strains listed (Fig. 1A and Table I).

211 The direct binding of sSIGNR1 to *C. albicans* J-1012 N-glycan, which is composed of
212 complexed side chains, was inhibited by glycans from several types of microbes: *C. albicans*
213 NIH B-792 and *C. stellatoidea* glycans lacking β 1,2-mannose, *C. parapsilosis* glycan
214 lacking β 1,2-mannose and α 1,6-branched mannose, and *S. cerevisiae* WT glycan composed of
215 short side chains lacking β 1,2-mannose and α 1,6-branched mannose (Fig. 2A). These glycans
216 share the α 1,2-mannose side chain structure, suggesting that SIGNR1 recognizes similar moiety
217 in N-glycan as hDC-SIGN (2). Moreover, *S. cerevisiae* 4484-24D-1 (*mnn1/mnn4*) glycan, which
218 lacks phosphorylated mannose (PM), β 1,2-mannose, α 1,3-mannose, and α 1,6-branched mannose
219 but possesses the short (mono- or di-) mannose side chain structure, appeared to be recognized
220 by SIGNR1. However, *S. cerevisiae* X2180-1A-5 (*mnn2*) glycan, which lacks all side chains,
221 wasn't effective (Figs. 2A and B), suggesting the crucial involvement of the side chain structure.
222 In addition, *C. lusitaniae* glycan, the side chain of which is composed of more than 75% of
223 β 1,2-mannose (mono- ~ tri- β -mannose)-capped side chain (23), was also ineffective in inhibiting
224 the sSIGNR1 binding (Figs. 2A and B), implying that these β 1,2- mannoses disturb the access of

SIGNR1 to the α -di-mannose to some extent. Glycogen itself had no effect. As in the case of sSIGNR1 binding to microbes, that to *C. albicans* J-1012–derived N-glycan was EDTA-sensitive (Fig. 2A).

Interestingly, treatment of *C. albicans* J-1012 mannan with α -mannosidase, which removed the α -mannose side chains other than the β 1,2-mannose-capped side chains (see Fig. 1B) (14), did not affect the inhibitory activity (Fig. 2A). This result also indicates that β 1,2-mannose capped α -mannose side chains in the N-glycan are sufficient to be recognized by SIGNR1. We also obtained similar results when mannan from *S. cerevisiae* (M7504; Sigma-Aldrich) was employed to coat plastic plates in lectin ELISA (data not shown). Therefore, it is feasible that SIGNR1 recognizes long internal α -mannose (tri- or more-mannose) capped with β 1,2-mannose in addition to α -mannose side chains.

Since RAW-SIGNR1 cells effectively bind and endocytose high molecular weight FITC-dextran in an EDTA-sensitive manner (27), we carried out the inhibition analysis using RAW-SIGNR1 cells to bind FITC-dextran instead of lectin ELISA (Fig. 2C). The inhibition activities of glycans from *C. albicans* J-1012 and NIH B-792, and *S. cerevisiae* and its mutant (*mnn1/mnn4*) were again comparably effective. The treatment of *C. albicans* J-1012 glycan with α -mannosidase was also ineffective in reducing the inhibitory activity. In addition, low efficiencies of glycans from *S. cerevisiae* (*mnn2*) and *C. lusitaniae* were also confirmed in this experimental system. When resident peritoneal M ϕ that express SIGNR1 (27) were used, similar

results were obtained (data not shown). Together with the results using N-glycan only consisting of α -mannose in side chain, these results strengthen the possibility that SIGNR1 recognizes both α -mannose side chain and β 1,2-mannose capped α -mannose side chains composed of more than tri-mannoses in N-glycan.

Specificity of N-glycan recognition by hDC-SIGN. Cambi *et al.* previously reported that hDC-SIGN recognizes glycans of *S. cerevisiae* strains less efficiently than those of *Candida* strains (2). In contrast, SIGNR1 equally recognized glycans from both wild type and *mn1/mn4* mutant of *S. cerevisiae* as *C. albicans*, suggesting that the specificities of hDC-SIGN and SIGNR1 are somehow different from each other. In order to examine this possibility, we prepared shDC-SIGN and compared the sugar specificity with that of sSIGNR1.

In lectin ELISA, the binding of shDC-SIGN to *C. albicans* J-1012 glycan was more sensitive to fucose than mannose, and less sensitive to glucose and GlcNAc (Fig. 3A), as reported (16). Results using this probe showed that shDC-SGIN bound comparably well to *C. albicans* J-1012 and NIH B-792 (Fig. 3B). Unlike sSIGNR1, shDC-SIGN bound less to *S. cerevisiae* microbes, as reported (2).

In addition, shDC-SIGN binding to *C. albicans* J-1012 glycan was not efficiently blocked by glycans from *S. cerevisiae* and *mn1/mn4* mutants (Fig. 3C), indicating different specificity in N-glycan recognition between hDC-SIGN and SIGNR1. It is worth noting that

treating *C. albicans* J-1012 glycan with α -mannosidase dramatically reduced its inhibitory activity (Fig. 3C). We further confirmed the abrogation of inhibitory activity of N-glycan from *C. albicans* J-1012 by α -mannosidase treatment by titrating its dose (Fig. 3D), showing that the reduced activity is nearly comparable to that of *S. cerevisiae*. These results suggested that hDC-SIGN only recognizes the α 1,2-mannose at the non-reductive end of α -mannose side chains, but not the internal α 1,2-mannose capped with β 1,2-mannose and short α -mannose chains that are recognized by SIGNR1, of the N-glycan side chains in mannoprotein.

It has been reported that another SIGNR lectin, SIGNR3, also recognizes *C. albicans* (27) and that its saccharide specificity resembles that of hDC-SIGN (20). Based on the inhibition assay using lectin ELISA, SINGR3 was shown to bind a little more efficiently to wild type and the *mn1/mn4* mutant of *S. cerevisiae* than hDC-SIGN but less so than SIGNR1 (Supplementary Fig. S2).

Glyco-microarray analyses of SIGNR1 and hDC-SIGN. Previously, Powlesland *et al.* reported that sSIGNR1 did not bind any ligand on array using the regular method (20), suggesting a weak affinity of SIGNR1. However, a sensitive glyco-microarray, based on an evanescent-field fluorescence-assisted detection, has recently been developed (28). This method, in which analysis was performed in the presence of lectin probe without washing, enabled us to detect weak glycan-lectin interactions in the equilibrium state (15, 29), possibly representing

genuine interactions of ligand and cellular lectin.

An array plate immobilized with the glycans indicated (Fig. 4A and Supplementary Fig. S1) was visualized by staining with Alexa647-coupled sSIGNR1/anti-SIGNR1 mAb complex (Fig. 4B). The results clearly show that SIGNR1 binds to α -mannose and yeast mannans from *C. albicans* and *S. cerevisiae*, but not β -mannose, in an EDTA-sensitive manner (Figs. 4B and C). Of note, SIGNR1 did not recognize fucose-containing moieties, such as Fuc α 2Gal and Lewis^{a/b/x/y} antigen. The binding of sSIGNR1 to heparin is likely to be false positive, because of the insensitivity to EDTA.

We previously performed array analyses using shDC-SIGN-Fc fusion as a probe (28). However, structural forms between SIGNR1 and shDC-SIGN-Fc were different and this made it difficult to compare the precise sugar specificities. Therefore, we again performed glyco-array analysis using shDC-SIGN dimer as in sSIGNR1. The results clearly showed the recognition of fucose-containing glycans and *C. albicans*, but not *S. cerevisiae*, mannan by shDC-SIGN (Fig. 4D), being consistent with our results in lectin ELISA and direct binding to microbes.

However, there are some discrepancies in our current observation and previous array results. It has been shown that SIGNR1 can recognize fucose-containing moiety using glyco-array and solid phase competition binding assays (5). One of our previous microarray analyses also demonstrated that hDC-SIGN-Fc fusion was able to bind to glycans from *C. albicans* and *S. cerevisiae* (28). In both reports, lectin CRD was fused with the Fc portion of IgG

and polymerized with anti-Fc polyclonal Ab, giving rise to a very large and multi-valent complexed probe. In the current glyco-microarray analyses, we utilized dimerized lectin probes, which possibly have lower avidity than those used in previous studies, enabling us to uncover the difference in binding activity of shDC-SIGN to *S. cerevisiae* and *C. albicans* glycan.

Biological significance of the different sugar specificity between SIGNR1 and hDC-SIGN in IL-10 production using RAW264.7 transfectants. To examine the biological significance of distinct saccharide recognition between SIGNR1 and hDC-SIGN, we measured IL-10 production by RAW-SIGNR1 and RAW-hDC-SIGN cells, because hDC-SIGN on DCs is known to induce IL-10 production by recognizing *C. albicans* (7), and lamina propria DCs expressing SIGNR1 are also capable of producing IL-10 (30). After stimulation with *C. albicans* J-1012 microbe and glycan coated on plastic plate, RAW-hDC-SIGN, but not RAW-SIGNR1, produced IL-10 (data not shown). Therefore, we prepared RAW264.7 cells expressing the chimeric hDC-SIGN molecule (RAW-chimera), of which CRD was replaced with SIGNR1 CRD, to compare glycan recognition specificity in terms of the induction of IL-10 production. The RAW-chimera cells expressed comparable levels of lectin to that of RAW-hDC-SIGN cells (Fig. 5A). Upon stimulation with *S. cerevisiae* X2180-1A (WT) glycan, RAW-hDC-SIGN and RAW-chimera cells produced equivalent amounts of IL-10 (Fig. 5B, *upper panel*). RAW-hDC-SIGN produced much less IL-10 in response to *S. cerevisiae* than *C. albicans* glycan in comparison with

320 RAW-chimera (Fig. 5B, *lower panel*). Interestingly, in the case of *C. albicans* J-1012 glycan,
321 RAW-hDC-SIGN produced more IL-10 than RAW-chimera (Fig. 5B, *upper panel*). However,
322 the former significantly reduced IL-10 production after α -mannosidase treatment compared with
323 the latter (Fig. 5C), being consistent with the results showing that SIGNR1, but not hDC-SING,
324 recognizes β -mannose capped α -mannose side chains in *C. albicans* glycan.

325 It is feasible that *C. albicans* induces higher IL-10 production than *S. cerevisiae* via
326 hDC-SIGN on DCs in humans, leading to the immunosuppressive milieu at the site of infection.
327 This may explain why *C. albicans* is more virulent than *S. cerevisiae*. Regarding the sugar
328 specificity of SIGNR1, there were no significant differences in the binding specificity to
329 mannose moieties between *C. albicans* and *S. cerevisiae* at the molecular level. However, IL-10
330 production was slightly but significantly higher in response to *C. albicans* than *S. cerevisiae*,
331 implying that cellular responses by the recognition through lectin receptors is affected by some
332 other unknown factors. In this study, we used glycans prepared from the blastospore (yeast) form
333 of each yeast strain. However, it should also be kept in mind that the difference in the growth
334 form between *C. albicans* and *S. cerevisiae* might modulate cellular activity against microbes *in*
335 *situ*. hDC-SIGN in the mouse cells prepared in this study properly transduce signals for IL-10
336 production. Although it is unknown how hDC-SIGN activates the mouse Src family and
337 subsequent Raf-1 kinase in this situation, hDC-SIGN likely has a certain motif that is lacking in
338 SIGNR1, to work in both human and mouse cells for IL-10 production.

339

340 Collectively, SIGNR1 and hDC-SIGN bind polysaccharides in surface mannoprotein

341 on live *C. albicans*. However, SIGNR1 recognizes both α -mannose and β 1,2-mannose capped

342 α -mannose side chains composed of more than tri-mannoses, whereas hDC-SIGN recognizes

343 only α -mannose at the non-reductive end of the side chains, but not internal α -mannose capped

344 with β 1,2-mannose and short α -mannose chains, of N-glycan side chains in mannoprotein.

345 Differential recognition of yeast strains by SIGNR1 and hDC-SIGN may be relevant to the

346 differences in cellular responsiveness.

347

347 **Acknowledgment**

348 This work was supported in part by a Grant-in-Aid for Scientific Research (19590389
349 to KT and 18390121 and 20390109 to KI) and a Grant-in-Aid for Scientific Research on Priority
350 Area (19041036 to KT) from the Ministry of Education, Science, Sports and Culture of Japan
351 and by the Hokuto Foundation for Bioscience (KT) and the Naito Foundation (KI).

352

352 References

- 353 1. **Ballou, C. E., K. A. Kern, and W. C. Raschke.** 1973. Genetic control of yeast mannan
354 structure. Complementation studies and properties of mannan mutants. *J. Biol. Chem.*
355 **248**:4667-4671.
- 356 2. **Cambi, A., M. G. Netea, H. M. Mora-Montes, N. A. Gow, S. V. Hato, D. W. Lowman,**
357 **B. J. Kullberg, R. Torensma, D. L. Williams, and C. G. Figdor.** 2008. Dendritic cell
358 interaction with *Candida albicans* critically depends on N-linked mannan. *J. Biol. Chem.*
359 **283**:20590-20599.
- 360 3. **Chen, C., and H. Okayama.** 1987. High-efficiency transformation of mammalian cells
361 by plasmid DNA. *Mol. Cell. Biol.* **7**:2745-2752.
- 362 4. **Dupasquier, M., P. Stoitzner, A. van Oudenaren, N. Romani, and P. J. Leenen.** 2004.
363 Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse
364 dermis. *J. Invest. Dermatol.* **123**:876-879.
- 365 5. **Galustian, C., C. G. Park, W. Chai, M. Kiso, S. A. Bruening, Y. S. Kang, R. M.**
366 **Steinman, and T. Feizi.** 2004. High and low affinity carbohydrate ligands revealed for
367 murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing
368 specificities for SIGN-R3 and langerin. *Int. Immunol.* **16**:853-866.
- 369 6. **Gantner, B. N., R. M. Simmons, and D. M. Underhill.** 2005. Dectin-1 mediates
370 macrophage recognition of *Candida albicans* yeast but not filaments. *EMBO J.*

- 371 **24:1277-1286.**
- 372 7. **Geijtenbeek, T. B., S. J. Van Vliet, E. A. Koppel, M. Sanchez-Hernandez, C. M.**
373 **Vandenbroucke-Grauls, B. Appelmelk, and Y. Van Kooyk.** 2003. Mycobacteria target
374 DC-SIGN to suppress dendritic cell function. *J. Exp. Med.* **197**:7-17.
- 375 8. **Geijtenbeek, T. B. H., and S. I. Gringhuis.** 2009. Signalling through C-type lectin
376 receptors: shaping immune responses. *Nat Rev Immunol* **9**:465-479.
- 377 9. **Kang, Y. S., Y. Do, H. K. Lee, S. H. Park, C. Cheong, R. M. Lynch, J. M. Loeffler, R.**
378 **M. Steinman, and C. G. Park.** 2006. A dominant complement fixation pathway for
379 pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. *Cell*
380 **125**:47-58.
- 381 10. **Kang, Y. S., S. Yamazaki, T. Iyoda, M. Pack, S. A. Bruening, J. Y. Kim, K.**
382 **Takahara, K. Inaba, R. M. Steinman, and C. G. Park.** 2003. SIGN-R1, a novel C-type
383 lectin expressed by marginal zone macrophages in spleen, mediates uptake of the
384 polysaccharide dextran. *Int. Immunol.* **15**:177-186.
- 385 11. **Khoo, U. S., K. Y. Chan, V. S. Chan, and C. L. Lin.** 2008. DC-SIGN and L-SIGN: the
386 SIGNs for infection. *J. Mol. Med.* **86**:861-874.
- 387 12. **Kitamura, T.** 1998. New experimental approaches in retrovirus-mediated expression
388 screening. *Int. J. Hematol.* **67**:351-359.
- 389 13. **Klena, J., P. Zhang, O. Schwartz, S. Hull, and T. Chen.** 2005. The core

- lipopolysaccharide of *Escherichia coli* is a ligand for the dendritic-cell-specific
intercellular adhesion molecule nonintegrin CD209 receptor. *J. Bacteriol.*
187:1710-1715.
14. **Kobayashi, H., N. Shibata, H. Mitobe, Y. Ohkubo, and S. Suzuki.** 1989. Structural
study of phosphomannan of yeast-form cells of *Candida albicans* J-1012 strain with
special reference to application of mild acetolysis. *Arch. Biochem. Biophys.*
272:364-375.
15. **Kuno, A., N. Uchiyama, S. Koseki-Kuno, Y. Ebe, S. Takashima, M. Yamada, and J.
Hirabayashi.** 2005. Evanescent-field fluorescence-assisted lectin microarray: a new
strategy for glycan profiling. *Nat Methods* **2**:851-856.
16. **Mitchell, D. A., A. J. Fadden, and K. Drickamer.** 2001. A novel mechanism of
carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit
organization and binding to multivalent ligands. *J. Biol. Chem.* **276**:28939-28945.
17. **Nagaoka, K., K. Takahara, K. Tanaka, H. Yoshida, R. M. Steinman, S. Saitoh, S.
Akashi-Takamura, K. Miyake, Y. S. Kang, C. G. Park, and K. Inaba.** 2005.
Association of SIGNR1 with TLR4-MD-2 enhances signal transduction by recognition of
LPS in gram-negative bacteria. *Int. Immunol.* **17**:827-836.
18. **Netea, M. G., G. D. Brown, B. J. Kullberg, and N. A. Gow.** 2008. An integrated model
of the recognition of *Candida albicans* by the innate immune system. *Nat Rev Microbiol*

409 6:67-78.

410 19. **Park, C. G., K. Takahara, E. Umemoto, Y. Yashima, K. Matsubara, Y. Matsuda, B.**

411 **E. Clausen, K. Inaba, and R. M. Steinman.** 2001. Five mouse homologues of the

412 human dendritic cell C-type lectin, DC-SIGN. *Int. Immunol.* **13**:1283-1290.

413 20. **Powlesland, A. S., E. M. Ward, S. K. Sadhu, Y. Guo, M. E. Taylor, and K.**

414 **Drickamer.** 2006. Widely divergent biochemical properties of the complete set of mouse

415 DC-SIGN-related proteins. *J. Biol. Chem.* **281**:20440-20449.

416 21. **Raschke, W. C., K. A. Kern, C. Antalis, and C. E. Ballou.** 1973. Genetic control of

417 yeast mannan structure. Isolation and characterization of mannan mutants. *J. Biol. Chem.*

418 **248**:4660-4666.

419 22. **Shibata, N., K. Ikuta, T. Imai, Y. Satoh, R. Satoh, A. Suzuki, C. Kojima, H.**

420 **Kobayashi, K. Hisamichi, and S. Suzuki.** 1995. Existence of branched side chains in

421 the cell wall mannan of pathogenic yeast, *Candida albicans*. Structure-antigenicity

422 relationship between the cell wall mannans of *Candida albicans* and *Candida parapsilosis*.

423 *J. Biol. Chem.* **270**:1113-1122.

424 23. **Shibata, N., H. Kobayashi, Y. Okawa, and S. Suzuki.** 2003. Existence of novel

425 beta-1,2 linkage-containing side chain in the mannan of *Candida lusitanae*, antigenically

426 related to *Candida albicans* serotype A. *Eur. J. Biochem.* **270**:2565-2575.

427 24. **Shibata, N., N. Senbongi, T. Hosoya, K. Kawahara, R. Akagi, A. Suzuki, H.**

- 428 **Kobayashi, S. Suzuki, and Y. Okawa.** 1997. Demonstration of the presence of
- 429 alpha-1,6-branched side chains in the mannan of *Candida stellatoidea*. *Eur. J. Biochem.*
- 430 **246**:477-485.
- 431 25. **Shibata, N., A. Suzuki, H. Kobayashi, and Y. Okawa.** 2007. Chemical structure of the
- 432 cell-wall mannan of *Candida albicans* serotype A and its difference in yeast and hyphal
- 433 forms. *Biochem. J.* **404**:365-372.
- 434 26. **Takahara, K., S. Tokieda, K. Nagaoka, T. Takeda, Y. Kimura, and K. Inaba.** 2011.
- 435 C-type lectin SIGNR1 enhances cellular oxidative burst response against *C. albicans* in
- 436 cooperation with Dectin-1. *Eur. J. Immunol.* **41**:1435-1444.
- 437 27. **Takahara, K., Y. Yashima, Y. Omatsu, H. Yoshida, Y. Kimura, Y. S. Kang, R. M.**
- 438 **Steinman, C. G. Park, and K. Inaba.** 2004. Functional comparison of the mouse
- 439 DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. *Int. Immunol.* **16**:819-829.
- 440 28. **Tateno, H., A. Mori, N. Uchiyama, R. Yabe, J. Iwaki, T. Shikanai, T. Angata, H.**
- 441 **Narimatsu, and J. Hirabayashi.** 2008. Glycoconjugate microarray based on an
- 442 evanescent-field fluorescence-assisted detection principle for investigation of
- 443 glycan-binding proteins. *Glycobiology* **18**:789-798.
- 444 29. **Uchiyama, N., A. Kuno, H. Tateno, Y. Kubo, M. Mizuno, M. Noguchi, and J.**
- 445 **Hirabayashi.** 2008. Optimization of evanescent-field fluorescence-assisted lectin
- 446 microarray for high-sensitivity detection of monovalent oligosaccharides and

Takahara *et al.*

447 glycoproteins. *Proteomics* **8**:3042-3050.

448 30. **Zhou, Y., H. Kawasaki, S. C. Hsu, R. T. Lee, X. Yao, B. Plunkett, J. Fu, K. Yang, Y.**

449 **C. Lee, and S. K. Huang.** 2010. Oral tolerance to food-induced systemic anaphylaxis

450 mediated by the C-type lectin SIGNR1. *Nat. Med.* **16**:1128-1133.

451

452

Figure legends

Fig. 1. sSIGNR1 binds various types of yeast strains.

(A) Structural diagrams of N-glycan used in this study. Structures of N-glycan of *C. albicans* J-1012 (25), *C. albicans* NIH B-792 (22), *C. stellatoidea* (24), *C. parapsilosis* (22) and *C. lusitaniae* (23) are adopted from our structural analyses using NMR. Structure of *S. cerevisiae* wild type, *S. cerevisiae* 4484-24D-1 (*mnn1/mnn4*) and *S. cerevisiae* X2180-1-A-5 (*mnn2*) are based on previous reports (1, 21). Side chains that are digested by treatment with α -mannosidase in *C. albicans* J-1012 N-glycan are *shaded*. The side chain sequence is not specified. (B) Binding of sSIGNR1 to *Candida* and *S. cerevisiae* strains. PE-*Strep*-Tactin alone (-) or PE-sSIGNR1 (+) were incubated with the indicated live yeast strains with or without EDTA (25 mM). (C) Inhibition of sSIGNR1 binding to *C. albicans* J-1012 by glycans purified from the *C. albicans* and *S. cerevisiae* strains indicated. sSIGNR1 was pre-incubated with 50 μ g/ml of glycans before mixing with microbes. Glycogen was used as a negative control. Inhibition is indicated as the percent decrease of fluorescence intensity in experimental groups compared with the control without inhibitor. The results are shown as the mean \pm SD of triplicate assays. * $p < 0.05$ on solid line by Tukey's multiple range test. Grey lines show no significant differences.

Fig. 2. Recognition of α -mannose side chains in N-glycan by sSIGNR1.

(A) Inhibition analysis by lectin ELISA. Binding of sSIGNR1 to *C. albicans* J-1012 glycan

coated on microtiter plates was analyzed in the presence of glycans (25 μ g/ml) purified from various types of yeast strains. Blocking activities of inhibitors are shown as the % inhibition of sSIGNR1 binding. (B) Titration of inhibitory activity of glycans from the indicated yeast strains for sSIGNR1 binding by lectin ELISA. Half of maximal inhibition activity was indicated by dashed line. (C) Inhibition of FITC-binding to RAW-SIGNR1 cells by glycans. Transfectants were incubated with the graded dose of glycans as in (B) prior to FITC-dextran. The results are shown as % inhibition. Results are shown as the mean \pm SD of triplicate assays. $*p < 0.05$ on solid line by Tukey's multiple range test. Grey lines show no significant differences.

Fig. 3. Binding of shDC-SIGN to microbes and inhibition of shDC-SIGN binding by glycans.

(A) Inhibition analysis of shDC-SIGN binding by monosaccharides (50 mM) and glycan from *C. albicans* J-1012 using lectin ELISA. (B) Binding of shDC-SIGN to yeast strains was analyzed as in Fig. 1B. (C) Inhibition analysis using glycans from various yeast strains as in Fig. 2A. (D) Inhibition assay was performed in the presence of graded doses of glycans from the indicated yeast strains. Half of maximal inhibition activity was indicated by dashed line. The results are shown as the mean \pm SD of triplicate assays. $*p < 0.05$ on solid line by Tukey's multiple range test. Grey lines show no significant differences.

Fig. 4. Glyco-microarray analysis of sSIGNR1.

490 (A) The layout of glyco-microarray. (B) Results of the glyco-microarray analyses. Binding of
491 soluble SIGNR1/Alexa647-anti-SIGNR1 mAb immune complex to the array was performed in
492 the absence (*left panel*) or presence (*right panel*) of 10 mM EDTA and detected by an
493 evanescent-field fluorescence-assisted scanner. (C) Data analyzed with the Array Pro analyzer
494 ver. 4.5. (D) Glyco-array analysis was performed using immune complex of soluble
495 hDC-SIGN/Alexa555-anti-hDC-SIGN mAb as in sSIGNR1.

496
497 Fig. 5. IL-10 production of RAW264.7 transfectants upon stimulation with glycan coated on
498 plastic plate.

499 (A) RAW-control, RAW-hDC-SIGN and RAW-chimera cells were analyzed by flowcytometry
500 using polyclonal anti-hDC-SIGN Ab and anti-SIGNR1 mAb (22D1) specific to SIGNR1 CRD.
501 (B) The transfectants (5×10^4 cells) were cultured on plates pre-coated with *C. albicans* J-1012
502 and *S. cerevisiae* X2180-1A (WT) glycan in the presence or absence of LPS (100 ng/ml). After
503 24 h, IL-10 in the supernatants was analyzed (*upper panel*). IL-10 production against *S.*
504 *cerevisiae* glycan is shown as a percentage to that against *C. albicans* glycan (*lower panel*). (C)
505 IL-10 production after stimulation with native and α -mannosidase-treated *C. albicans* J-1012
506 glycan was analyzed as in B. IL-10 production against the treated glycan is shown as a
507 percentage to that against the native glycan. $**p = 0.0067$, $***p = 0.0001$ by Student's *t*-test.


1 TABLE 1. Composition of side chains and properties of N-glycan used in this study.

N-glycan	Presence of side chain ^a				
	α1,3-mannose	α1,2-mannose	α1,6-mannose ^b	β1,2-mannose	PM
<i>C. albicans</i> J-1012 (serotype A)	+	+	+	+	+
<i>C. albicans</i> NIH B-792 (serotype B)	+	+	+	+	+
<i>S. cerevisiae</i> (WT)	-	+	-	-	+
<i>S. cerevisiae</i> 4484-24D-1 (<i>mn1/mnn4</i>)	-	+	-	-	-
<i>S. cerevisiae</i> X2180-1A-5 (<i>mnn2</i>)	-	-	-	-	-
<i>C. stellatoidea</i>	+	+	+	-	-
<i>C. parapsilosis</i>	+	+	-	-	-
<i>C. lusitaniae</i>	-	+	-	+	+
<i>C. albicans</i> J-1012 (α-mannosidase treated)	+	+	-	+	-


17 ^a PM, phosphorylated mannose. Side chain structure presence and absence in the N-glycan are indicated by + and -, respectively.

18 ^b Branching in side chain.


A




B




C




Takahara *et al.* Fig. 1.




Takahara *et al.* Fig. 2.






Takahara *et al.* Fig. 4.



Trivial name	Presentatio n	Glycans	Co.	Cat#
α Fuc	PAA	Fuc α 1-PAA	Glycotech	01-007
Fuc α 2Gal	PAA	Fuc α 1,2Gal β 1-PAA	Glycotech	01-019
Fuc α 3GlcNAc	PAA	Fuc α 1-3GlcNAc β 1-PAA	Glycotech	01-024
Fuc α 4GlcNAc	PAA	Fuc α 1-4GlcNAc β 1-PAA	Glycotech	01-025
H type1	PAA	Fuc α 1-2Gal β 1-3GlcNAc β 1-PAA	Glycotech	01-037
H type2	PAA	Fuc α 1-2Gal β 1-4GlcNAc β 1-PAA	Glycotech	08-034
H type3	PAA	Fuc α 1-2Gal β 1-3GalNAc α 1-PAA	Glycotech	08-060
A	PAA	GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc β 1-PAA	Glycotech	08-091
B	PAA	Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc β 1-PAA	Glycotech	08-092
Le ^a	PAA	Gal β 1-3(Fuc α 1-4)GlcNAc β 1-PAA	Glycotech	01-035
[3S]Le ^a	PAA	(3OSO ₃)Gal β 1-3(Fuc α 1-4)GlcNAc β 1-PAA	Glycotech	01-040
Le ^b	PAA	Fuc α 1-2Gal β 1-3(Fuc α 1-3)GlcNAc β 1-PAA	Glycotech	08-042
Le ^c	PAA	Gal β 1-4(Fuc α 1-3)GlcNAc β 1-PAA	Glycotech	01-036
Le ^d	PAA	Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc β 1-PAA	Glycotech	08-043
α Neu5Ac	PAA	Neu5Ac α 2-PAA	Glycotech	01-012
α Neu5Gc	PAA	Neu5Gc α 2-PAA	Glycotech	01-051
Sia2	PAA	Neu5Ac α 2-8Neu5Ac α 2-PAA	Glycotech	08-064
Sia3	PAA	Neu5Ac α 2-8Neu5Ac α 2-8Neu5Ac α 2-PAA	Glycotech	01-081
3'Siale ^a	PAA	Neu5Ac α 2-3Gal β 1-3GlcNAc β 1-PAA	Glycotech	01-078
3'SL	PAA	Neu5Ac α 2-3Gal β 1-4Glc β 1-PAA	Glycotech	01-038
3'SLN	PAA	Neu5Ac α 2-3Gal β 1-4GlcNAc β 1-PAA	Glycotech	01-077
sLe ^a	PAA	Neu5Ac α 2-3Gal β 1-3(Fuc α 1-4)GlcNAc β 1-PAA	Glycotech	08-044
sLe ^a	PAA	Neu5Ac α 2-3Gal β 1-4(Fuc α 1-3)GlcNAc β 1-PAA	Glycotech	01-045
6'SL	PAA	Neu5Ac α 2-6Gal β 1-4Glc β 1-PAA	Glycotech	01-039
FET	Glycoprotein	Fetuin (Complex-type N-glycans and O-glycans)	Sigma	F3004
AGP	Glycoprotein	α 1-acid glycoprotein (Complex-type N-glycans-)	Sigma	G9885
TF	Glycoprotein	Transferrin (Complex-type N-glycans)	Sigma	T3309
TG	Glycoprotein	Porcine thyroglobulin (Complex and high-mannnose-type N-glycans)	Sigma	T1126
β Gal	PAA	Gal β 1-PAA	Glycotech	01-004
[3S] β Gal	PAA	(3OSO ₃)Gal β 1-PAA	Glycotech	01-015
A-di	PAA	GalNAc di-3Gal β 1-PAA	Glycotech	01-017
Lac	PAA	Gal β 1-4Glc β 1-PAA	Glycotech	01-021
Le ^c	PAA	Gal β 1-3GlcNAc β 1-PAA	Glycotech	01-020
[3'S]Le ^a	PAA	(3OSO ₃)Gal β 1-3GlcNAc β 1-PAA	Glycotech	01-062
LN	PAA	Gal β 1-4GlcNAc β 1-PAA	Glycotech	01-022
[3'SLN	PAA	(3OSO ₃)Gal β 1-4GlcNAc β 1-PAA	Glycotech	01-061
[6'SLN	PAA	Gal β 1-4(6OSO ₃)GlcNAc β 1-PAA	Glycotech	01-066
[6'SLN	PAA	(6OSO ₃)Gal β 1-4GlcNAc β 1-PAA	Glycotech	01-068
β GalNAc	PAA	GalNAc β 1-PAA	Glycotech	01-011
di-GalNAc β	PAA	GalNAc β 1-3GalNAc β 1-PAA	Glycotech	01-070
LDN	PAA	GalNAc β 1-4GlcNAc β 1-PAA	Glycotech	01-057
GA2	PAA	GalNAc β 1-4Gal β 1-4Glc β 1-PAA	Glycotech	08-074
Asialo-FET	Glycoprotein	Asialo fetuin (Desialylated complex-type N- and O-glycans)	Sigma	F3004 (Acid-treated)
Asialo-AGP	Glycoprotein	Asialo α 1-acid glycoprotein (Desialylated complex-type N-glycans)	Sigma	G9885 (Acid-treated)
Asialo-TF	Glycoprotein	Asialo transferrin (Desialylated complex-type N-glycans)	Sigma	T3309 (Acid-treated)
Asialo-TG	Glycoprotein	Asialo porcine thyroglobulin (Desialylated complex-type N-glycans, high-mannnose-type N-glycans)	Sigma	T1126 (Acid-treated)

β GlcNAc	PAA	GlcNAc β -PAA	Glycotech	01-009
[6S] β GlcNAc	PAA	(6OSO ₃)GlcNAc β -PAA	Glycotech	01-016
Agalacto-Fet	Glycoprotein	Agalacto fetuin (Agalactosylated complex-type N- and O-glycans)	Sigma	F3004 (Galactosidase-treated)
Agalacto-AGP	Glycoprotein	Agalacto α 1-acid glycoprotein (Agalactosylated complex-type N-glycans)	Sigma	G9885 (Galactosidase-treated)
Agalacto-TF	Glycoprotein	Agalacto transferrin (Agalactosylated complex-type N-glycans, high-mannose-type N-glycans)	Sigma	T3309 (Galactosidase-treated)
OVM	Glycoprotein	Ovomucoid (Complex-type N-glycans)	Sigma	T2011
OVA	Glycoprotein	Ovoalbumin (Hybrid-type N-glycans)	Sigma	A2512
α Man	PAA	Man α 1-PAA	Glycotech	01-005
β Man	PAA	Man β 1-PAA	Glycotech	01-050
[6P]Man	PAA	(6OPO ₃)Man α 1-PAA	Glycotech	01-006
INV	Glycoprotein	Yeast invertase (High mannose-type N-glycans)	Sigma	I4504
Tn	PAA	GalNAc α 1-PAA	Glycotech	01-010
Core1	PAA	Gal β 1-3GalNAc α 1-PAA	Glycotech	08-023
Core2	PAA	Gal β 1-3(GlcNAc β 1-6)GalNAc α 1-PAA	Glycotech	01-083
Core3	PAA	GlcNAc β 1-3GalNAc α 1-PAA	Glycotech	01-071
Core4	PAA	GlcNAc β 1-3(GlcNAc β 1-6)GalNAc α 1-PAA	Glycotech	01-089
Forsman	PAA	GalNAc β 1-3GalNAc α 1-PAA	Glycotech	01-026
Core6	PAA	GlcNAc β 1-6GalNAc α 1-PAA	Glycotech	01-072
Core8	PAA	Gal α 1-3GalNAc α 1-PAA	Glycotech	01-028
[3'S]Core1	PAA	(3OSO ₃)Gal β 1-3GalNAc α 1-PAA	Glycotech	08-069
Gal β -Core3	PAA	Gal β 1-4GlcNAc β 1-3GalNAc α 1-PAA	Glycotech	01-116
Asialo-BSM	Glycoprotein	Asialo bovine submaxillary mucin (Tn)	Sigma	M3895 (Acid-treated)
Asialo-GP	Glycoprotein	Asialo human glycophorin MN (T)	Sigma	A9791 (Acid-treated)
STn	PAA	Neu5Ac α 2-6GalNAc α 1-PAA	Glycotech	01-059
STn (Gc)	PAA	Neu5Gc α 2-6GalNAc α 1-PAA	Glycotech	01-107
ST	PAA	Neu5Ac α 2-3Gal β 1-3GalNAc α 1-PAA	Glycotech	01-088
Sia α 2-6Core 1	PAA	Gal β 1-3(Neu5Ac α 2-6)GalNAc α 1-PAA	Glycotech	01-113
BSM	Glycoprotein	Bovine submaxillary mucin (Sialyl Tn)	Sigma	M3895
GP	Glycoprotein	Human glycophorin (Disialyl T and sialyl Tn)	Sigma	G5017
α Gal	PAA	Gal α 1-PAA	Glycotech	01-003
Gal α 1-2Gal	PAA	Gal α 1-2Gal β 1-PAA	Glycotech	01-056
Gal α 1-3Gal	PAA	Gal α 1-3Gal β 1-PAA	Glycotech	01-018
Gal α 1-3Lac	PAA	Gal α 1-3Gal β 1-4Glc β 1-PAA	Glycotech	01-075
Gal α 1-3LN	PAA	Gal α 1-3Gal β 1-4GlcNAc β 1-PAA	Glycotech	01-079
Gal α 1-4LN	PAA	Gal α 1-4Gal β 1-4GlcNAc β 1-PAA	Glycotech	01-110
Melittiose	PAA	Gal α 1-6Glc β 1-PAA	Glycotech	01-063
α Glc	PAA	Glc α 1-PAA	Glycotech	01-001
β Glc	PAA	Glc β 1-PAA	Glycotech	01-002
Maltose	PAA	Glc α 1-4Glc β 1-PAA	Glycotech	01-054
HA	BSA	Hyaluronic acid-BSA	Seikagaku	400720
CSA	BSA	Chondroitin Sulfate A-BSA	Seikagaku	400655
CSB	BSA	Chondroitin Sulfate B-BSA	Seikagaku	400660
HS	BSA	Heparan Sulfate-BSA	Seikagaku	400700
HP	BSA	Heparin-BSA	Calbiochem	375095
KS	BSA	Keratan Sulfate-BSA	Seikagaku	400760
α Rha	PAA	Rhamnose α 1-PAA	Glycotech	01-008
Mannan (SC)	Glycoprotein	<i>S. cerevisiae</i> mannan	Sigma	M7504
Mannan (CA)	Glycoprotein	<i>C. albicans</i> mannan	Takara	MG001
Zymosan	Glycoprotein	Zymosan	Sigma	Z4250
Chitobiose	PAA	GlcNAc β 1-4GlcNAc β 1-PAA	Glycotech	08-057
BSA	Glycoprotein	-	Sigma	A7638
Negative PAA	PAA	-	Glycotech	01-000

Takahara *et al.* Fig. S1.
Precise information of ligands on the glyco-microarray.



Takahara *et al.* Fig. S2.

Inhibition analysis by lectin ELISA. Binding of sSIGNR3 to *C. albicans* J-1012 glycan coated on microtiter plates was analyzed as in Fig. 2A.